She is prepared to acquire all of 23andMe's outstanding shares of common stock in cash for 40 cents per share, according to a filing with the SEC Wednesday.
23andMe has struggled to generate steady recurring revenue since customers only needed to take its DNA test once to get their results.Wojcicki said she was prepared to acquire all of 23andMe's outstanding shares of common stock in cash for 40 cents per share, according toThe proposed price of 40 cents per share reflects an 11% premium to 23andMe's closing stock price from April. Wojcicki's intention is to complete the transaction"as promptly as possible," the filing said.
Hemos resumido esta noticia para que puedas leerla rápidamente. Si estás interesado en la noticia, puedes leer el texto completo aquí. Leer más: